Prolongation of cardiac conduction times by intravenous aprindine in man.
The acute electrophysiologic effects of intravenous aprindine were evaluated in 48 patients to assess the effect on conduction times and refractoriness in patients with severe cardiac disease and arrhythmias. The patients had not responded to conventional antiarrhythmic medications or had been unable to tolerate effective doses of conventional medications because of side effects. Eleven patients had an abnormal H-V interval, 9 had prolonged QRS duration and 22 had evidence of severe left ventricular dysfunction. Aprindine prolonged conduction transiently in the atria, the atrioventricular (A-V) node, the His-Purkinje system and the ventricles. The refractory times of the atria, the A-V node and the ventricles increased insignificantly, both functionally and statistically. Atrioventricular block did not develop in any patient, and side effects were minor. Thus, aprindine can be safely administered intravenously (10 to 15 mg/min) to severely ill patients with arrhythmias that are refractory to other medications even in the presence of underlying conduction system and myocardial disease.
D000328:Adult; D000368:Aged; D001073:Aprindine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D001283:Atrioventricular Node / Q000187:drug effects; D002036:Bundle of His / Q000187:drug effects; D002304:Cardiac Pacing, Artificial; D004341:Drug Evaluation; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D011690:Purkinje Fibers / Q000187:drug effects
D007192:Indenes; D001073:Aprindine